Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 154 for “"MYCN"”.
-
Role of MYCN in Prostate Cancer
… et al., 2007; Zhu et al., 2021). The oncogene MYCN – known to play a central role in many cancers – is overexpressed in the NEPC subtype (J. K. Lee et al., 2016). Unfortunately, MYCN itself is considered “undruggable” (Wolpaw et al., 2021). However, MYCN is known to interact with partner …
-
The MYCN locus as an integrated oncogenic unit: noncoding mechanisms and improved modeling of MYCN-amplified neuroblastoma
… of pediatric cancer deaths. Amplification of MYCN is one of the strongest predictors of aggressive disease, rapid progression, and poor clinical outcome. Despite decades of research, experimental models of MYCN-driven neuroblastoma have focused predominantly on MYCN protein function and have …
-
Therapeutically targeting USP5 in MYCN-driven neuroblastoma
Advanced neuroblastoma is associated with MYCN amplification and gene amplification of MYCN has been shown to correlate with poor prognosis in patients. The MYC family of proteins have been widely researched due to their important roles in the development of various cancers including neuroblastoma. …
-
Epigenetic regulators contributing to MYCN-driven neuroblastoma
… showed significant anti-cancer efficacy against MYCN-amplified neuroblastoma both in vitro and in vivo. The combination therapy also synergistically reduced the expression of key oncogenic genes such as Bcl-2, LIN28B and N-Myc with minimum cytotoxicity on normal human fibroblast cells In …
-
Charakterisierung von Retinoblastomen mit Amplifikation des Onkogens MYCN
Amplification of the oncogene MYCN has been described in a minority of retinoblastomas with and without RB1 inactivation. It is assumed that MYCN amplified retinoblastomas are associated with a more aggressive clinical behavior and an unfavorable prognosis. In this dissertation, the incidence, RB1 …
-
MYCN is an RNA binding protein mediating transcript decay
The MYCN oncoprotein is frequently overexpressed in neuroblastoma, where it acts as a major driver of tumorigenesis. MYCN is a transcription factor that regulates gene expression through widespread promoter binding. However, the overall impact of MYCN on transcriptional output is modest, suggesting …
-
Analysis of MYCN and MAX alterations in Wilms Tumor
… common renal tumor in childhood. Among others, MYCN copy number gain and MYCN P44L and MAX R60Q mutations have been identified in WT. The proto-oncogene MYCN encodes a transcription factor that requires dimerization with MAX to activate transcription of numerous target genes. MYCN gain has been …
-
Downregulation of MYCN oncogene by retinoic acid in neuroblastoma
… tumors show the gene amplification of MYCN oncogene. Because MYCN plays a critical role, MYCN gene amplification is considered an important risk factor of neuroblastoma. Retinoic acid (RA) is one of the few agents which can improve the survival rate of patients in the high risk group. …
-
Die Telomerlänge als Prognosefaktor in MYCN nicht-amplifizierten Neuroblastomen
… Beispiel Alter bei Erstdiagnose, Tumorstadium, MYCN-Amplifikation und 1p Deletion, werden seit längerem zur Risikostratifizierung genutzt. Bereits in anderen Tumorerkrankungen konnte nun der Einfluß einer Telomerlängenveränderung auf das Gesamtüberleben von Patienten nachgewiesen werden. …
-
Development of MYCN inhibitors to treat high-risk neuroblastoma
… 50% chance of survival and experience relapse. MYCN is an oncogene belongs to the MYC family and is a major oncogenic driver of NB. Direct targeting MYCN has been challenging due to its structure with no deep pocket for direct binding of small molecules. Alternatively, indirectly targeting MYCN …
-
Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma
… Patients with high-risk neuroblastoma often show MYCN-amplification and elevated levels of Aurora-A. They have a low overall survival and despite multimodal therapy options a poor therapeutic prognosis. MYCN-amplified neuroblastoma cells depend on Aurora-A functionality. Aurora-A stabilizes MYCN …
-
Investigating Inhibition of MYCN in the Treatment of Wilms' Tumour
… Tumour subtype has displayed a greater level of MYCN expression, a known oncoprotein, and while genetic alteration of MYCN has been reported, no biological functional studies have been conducted. Here I have shown that MYCN depletion via small interfering RNA results in growth suppression whereas …
-
G9a as a potential therapeutic target in MYCN-amplified neuroblastomas
MYCN-amplification is a high-risk factor in neuroblastoma which contributes to a poor prognostic outcome. Here data is presented showing that both short-interfering RNA depletion and treatment by small molecule inhibitors (SMI) of lysine-specific histone methyltransferase Euchromatic Histone Lysine …
-
MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling
MYCN amplification drives half of all high-risk neuroblastomas and confers dismal prognosis. It occurs when MYCN and other chromosomal fragments are joined together to form an amplicon sequence that can be found tens to hundreds of times per cell. In most cases, these copies come as …
-
Developing immunocombination therapy for Neuroblastoma using a Mycn tumor model
Radboud Universiteit Nijmegen, 14 oktober 2015
-
From MYCN to inflammaging : understanding the pathogenesis of immature T-ALL
… T cells (Late). Early leukemias exhibited high MYCN expression, which correlated with poor clinical outcome in a large pediatric cohort. Knockout and knockdown experiments revealed Early leukemias to be dependent on MYCN for initial transformation and subsequent clonal propagation. Use of …
-
Inhibition von Aurora-A als neue Therapiestrategie gegen MYCN-amplifizierte Neuroblastome
Im Neuroblastom ist die Amplifikation des MYCN-Gens, das für den Transkriptionsfaktor N-Myc kodiert, der klinisch bedeutendste Faktor für eine schlechte Prognose. Als Mitglied der onkogenen Myc-Familie induziert N-Myc die Expression von Genen, die in vielen biologischen Prozessen wie Metabolismus, …
-
INHIBITION MYCN- VERMITTELTER ZELLZYKLUSTRANSITION DURCH THYROID CANCER 1 (TC1) IM NEUROBLASTOM – ETABLIERUNG UND CHARAKTERISIERUNG DES TC1- ÜBEREXPRESSIONSPHÄNOTYPS IN HUMANEN SH-EP NEUROBLASTOMZELLEN UNTER DEM EINFLUSS VON MYCN
… die Amplifikation und erhöhte Expression von MYCN dar. In Vorarbeiten der Arbeitsgruppe von Prof. Christiansen zeigte MYCN Einfluss auf die Genregion von Thyroid Cancer 1 (TC1), das als neuer Marker für maligne Schilddrüsenkarzinome erkannt wurde. In der vorliegenden Arbeit wurden erste …
Page 1 of 8